CD274 and neoplasm: Preclinical models of Cushing disease demonstrate PD-L1 expression in cell lines and cultured tumors as well as the effectiveness of anti-PD-L1 immunotherapy in reducing tumor mass, decreasing hormone secretion, and arresting tumor proliferation.